Conclusion GLP-1 receptor agonists have emerged as powerful agents that improve metabolic health lowering blood sugar, inducing weight loss, and reducing cardiovascular risk in patients with diabetes or obesity
Rom Biotechnol Lett 18:85598572 Boondaeng A, Kasemsumran S, Ngowsuwan K, Vaithanomsat P, Apiwatanapiwat W, Trakunjae C, Janchai P, Jungtheerapanich S, Niyomvong N (2021) Fermentation condition and quality evaluation of pineapple fruit wine
Put the needle at a 45-degree angle
These results indicate that treatment with GABA, DSIP-CBBBP and more effectively reduced wakefulness time, with DSIP-CBBBP showing the most substantial reduction, suggesting its potential as a therapeutic agent for mitigating insomnia
Mounjaro and Trulicity are approved in the United States for the treatment of type 2 diabetes
Cardiovascular effects incretin-based therapies have been associated with modest increases in heart rate